This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica (TéAGS)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Grenoble Identifier:
First received: March 14, 2013
Last updated: March 23, 2016
Last verified: March 2016
The purpose of this study is to determine whether anti-inflammatory drugs or glucocorticoids are effective in the treatment of acute sciatica

Condition Intervention Phase
Sciatica Drug: methylprednisolone Drug: Ketoprofen Drug: Sodium Chloride Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica

Resource links provided by NLM:

Further study details as provided by University Hospital, Grenoble:

Primary Outcome Measures:
  • Mean visual analogue scale (VAS) for leg pain (radicular pain) in 3 groups [ Time Frame: From day 0 to day 5 ]
    VAS is measured in millimiters (0 to 100). This pain score is recommended in rheumatologic units in France.

Secondary Outcome Measures:
  • Mean visual analogue scale (VAS) for back pain in 3 groups [ Time Frame: From day 0 to day 5 ]
    VAS is measured in millimeters (0 to 100).

  • Assess drug compliance [ Time Frame: From day 0 to day 5 ]
    Drug compliance is estimated based on the proportion of the treatment actually administered.

  • The effect of treatment on the EIFEL Questionnaire [ Time Frame: At baseline, 1 and 3 months after intervention ]
    The EIFEL questionnaire is the translation of the Roland Morris Disability Questionnaire (RMDQ) and has been validated in acute low back pain.

  • Improvement in Lasegue's sign compared to baseline [ Time Frame: At baseline, Day 1,2,3,4 and 5 of study period ]
    Lasegue's sign is the lumbar pain experienced by the patient on passive movement of the legs during flexion of hip joint i.e. passive straight leg raising. It is assessed as either 'Positive' or 'Negative' sign.

  • Assess Schober's test [ Time Frame: From Day 0 to Day 5 ]
    Schober's test is a test used in rheumatology to measure the ability of patient to flex their lower back

  • Analgesic consumption [ Time Frame: At baseline, day 0, 1, 2, 3, 4 and day 5, 1 and 3 months ]
    Analgesic consumption between active treatment group and placebo group was registered and differences between groups were calculated and presented as percentual differences.

  • Surgery or lumbar epidural injection [ Time Frame: At 1 and 3 months after intervention ]
    Number of patient having surgery and/or lumbar epidural injection during study period

  • Clinical tolerance: adverse events and/or high blood pressure [ Time Frame: at baseline, day 1, 2 3, 4 and 5 ]
    Number of adverse events and/or high blood pressure between intervention group.

  • Biological tolerance [ Time Frame: at baseline, day 3 and 5 ]
    measures of leukocytes, erythrocytes, hemoglobin, platelets, serum sodium, potassium, glucose, plasma creatinine between intervention group

  • Glycemic levels [ Time Frame: at baseline, day 1 to 5 ]
    monitoring of glycemic status is measured for each day of treatment

  • Number of days of hospitalisation sick leave, number of days lost to illness [ Time Frame: At baseline, 1 and 3 months ]
    To assess the cost of sciatica for society

Enrollment: 50
Study Start Date: January 2013
Study Completion Date: January 2016
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: methylprednisolone
administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
Drug: methylprednisolone Drug: Sodium Chloride
Active Comparator: Ketoprofen
administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
Drug: Ketoprofen
Placebo Comparator: sodium chloride
administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
Drug: Sodium Chloride


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • sciatica <8 weeks resistant to all treatments in ambulatory
  • Acute low back pain> 48 hours;
  • Non-deficit patients;
  • Initial VAS> 40/100;
  • Consent of patient
  • Conflict disco-radicular concordance with the clinical computed tomography scan or magnetic resonance imaging.
  • No of contraindications to methylprednisolone, ketoprofen;
  • No registration to another protocol;

Exclusion Criteria:

  • Pregnant, parturient, lactating mother;
  • Diabetic patient;
  • Patient with syndrome from narrowing of the lumbar vertebral canal
  • Patient with a history of lumbar surgery <1 year;
  • Patient with a Cauda equina syndrome or major motor disability;
  • Crural neuralgia
  • Patient with a deficit;
  • Suspicion of sciatica secondary, ie not conflict-related disco-root: infectious neuritis, fracture on spinal bone tumor ...

associated treatment or pathology contra-indicating administration methylprednisolone, ketoprofen.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01816334

CHU Hôpital Sud
Echirolles, France, 38130
CH d'Uriage
Uriage, France, 38410
Sponsors and Collaborators
University Hospital, Grenoble
  More Information

Responsible Party: University Hospital, Grenoble Identifier: NCT01816334     History of Changes
Other Study ID Numbers: 1201
Study First Received: March 14, 2013
Last Updated: March 23, 2016

Keywords provided by University Hospital, Grenoble:
Anti-Inflammatory Agents, Non-Steroidal

Additional relevant MeSH terms:
Neurologic Manifestations
Nervous System Diseases
Sciatic Neuropathy
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Anti-Inflammatory Agents
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents, Non-Steroidal
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents processed this record on September 20, 2017